Literature DB >> 19822626

Critically Ill patients with 2009 influenza A(H1N1) in Mexico.

Guillermo Domínguez-Cherit1, Stephen E Lapinsky, Alejandro E Macias, Ruxandra Pinto, Lourdes Espinosa-Perez, Alethse de la Torre, Manuel Poblano-Morales, Jose A Baltazar-Torres, Edgar Bautista, Abril Martinez, Marco A Martinez, Eduardo Rivero, Rafael Valdez, Guillermo Ruiz-Palacios, Martín Hernández, Thomas E Stewart, Robert A Fowler.   

Abstract

CONTEXT: In March 2009, novel 2009 influenza A(H1N1) was first reported in the southwestern United States and Mexico. The population and health care system in Mexico City experienced the first and greatest early burden of critical illness.
OBJECTIVE: To describe baseline characteristics, treatment, and outcomes of consecutive critically ill patients in Mexico hospitals that treated the majority of such patients with confirmed, probable, or suspected 2009 influenza A(H1N1). DESIGN, SETTING, AND PATIENTS: Observational study of 58 critically ill patients with 2009 influenza A(H1N1) at 6 hospitals between March 24 and June 1, 2009. Demographic data, symptoms, comorbid conditions, illness progression, treatments, and clinical outcomes were collected using a piloted case report form. MAIN OUTCOME MEASURES: The primary outcome measure was mortality. Secondary outcomes included rate of 2009 influenza (A)H1N1-related critical illness and mechanical ventilation as well as intensive care unit (ICU) and hospital length of stay.
RESULTS: Critical illness occurred in 58 of 899 patients (6.5%) admitted to the hospital with confirmed, probable, or suspected 2009 influenza (A)H1N1. Patients were young (median, 44.0 [range, 10-83] years); all presented with fever and all but 1 with respiratory symptoms. Few patients had comorbid respiratory disorders, but 21 (36%) were obese. Time from hospital to ICU admission was short (median, 1 day [interquartile range {IQR}, 0-3 days]), and all patients but 2 received mechanical ventilation for severe acute respiratory distress syndrome and refractory hypoxemia (median day 1 ratio of Pao(2) to fraction of inspired oxygen, 83 [IQR, 59-145] mm Hg). By 60 days, 24 patients had died (41.4%; 95% confidence interval, 28.9%-55.0%). Patients who died had greater initial severity of illness, worse hypoxemia, higher creatine kinase levels, higher creatinine levels, and ongoing organ dysfunction. After adjusting for a reduced opportunity of patients dying early to receive neuraminidase inhibitors, neuraminidase inhibitor treatment (vs no treatment) was associated with improved survival (odds ratio, 8.5; 95% confidence interval, 1.2-62.8).
CONCLUSION: Critical illness from 2009 influenza A(H1N1) in Mexico occurred in young individuals, was associated with severe acute respiratory distress syndrome and shock, and had a high case-fatality rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19822626     DOI: 10.1001/jama.2009.1536

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  331 in total

1.  Assessment of the efficacy of the neuraminidase inhibitor oseltamivir against 2009 pandemic H1N1 influenza virus in ferrets.

Authors:  Elena A Govorkova; Bindumadhav M Marathe; Ashley Prevost; Jerold E Rehg; Robert G Webster
Journal:  Antiviral Res       Date:  2011-05-27       Impact factor: 5.970

2.  Socio-economic disparities in mortality due to pandemic influenza in England.

Authors:  Paul D Rutter; Oliver T Mytton; Matthew Mak; Liam J Donaldson
Journal:  Int J Public Health       Date:  2012-08       Impact factor: 3.380

3.  The social determinants of health and pandemic H1N1 2009 influenza severity.

Authors:  Elizabeth C Lowcock; Laura C Rosella; Julie Foisy; Allison McGeer; Natasha Crowcroft
Journal:  Am J Public Health       Date:  2012-06-14       Impact factor: 9.308

Review 4.  The 2009 influenza A (H1N1) pandemic: what have we learned in the past 6 months.

Authors:  Carlos del Rio; Jeannette Guarner
Journal:  Trans Am Clin Climatol Assoc       Date:  2010

5.  Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virus.

Authors:  Jonathan A McCullers; Lee-Ann Van De Velde; Kim J Allison; Kristen C Branum; Richard J Webby; Patricia M Flynn
Journal:  Clin Infect Dis       Date:  2010-06-01       Impact factor: 9.079

6.  2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States.

Authors:  Wun-Ju Shieh; Dianna M Blau; Amy M Denison; Marlene Deleon-Carnes; Patricia Adem; Julu Bhatnagar; John Sumner; Lindy Liu; Mitesh Patel; Brigid Batten; Patricia Greer; Tara Jones; Chalanda Smith; Jeanine Bartlett; Jeltley Montague; Elizabeth White; Dominique Rollin; Rongbao Gao; Cynthia Seales; Heather Jost; Maureen Metcalfe; Cynthia S Goldsmith; Charles Humphrey; Ann Schmitz; Clifton Drew; Christopher Paddock; Timothy M Uyeki; Sherif R Zaki
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

7.  Acute febrile illness surveillance in a tertiary hospital emergency department: comparison of influenza and dengue virus infections.

Authors:  Olga D Lorenzi; Christopher J Gregory; Luis Manuel Santiago; Héctor Acosta; Ivonne E Galarza; Elizabeth Hunsperger; Jorge Muñoz; Duy M Bui; M Steven Oberste; Silvia Peñaranda; Carlos García-Gubern; Kay M Tomashek
Journal:  Am J Trop Med Hyg       Date:  2013-02-04       Impact factor: 2.345

8.  Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.

Authors:  Yoko Shoji; Alex Prokhnevsky; Brett Leffet; Nancy Vetter; Stephen Tottey; Shama Satinover; Konstantin Musiychuk; Moneim Shamloul; Joey Norikane; R Mark Jones; Jessica A Chichester; Brian J Green; Stephen J Streatfield; Vidadi Yusibov
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 9.  2009 H1N1 influenza.

Authors:  Seth J Sullivan; Robert M Jacobson; Walter R Dowdle; Gregory A Poland
Journal:  Mayo Clin Proc       Date:  2009-12-10       Impact factor: 7.616

Review 10.  How I treat influenza in patients with hematologic malignancies.

Authors:  Corey Casper; Janet Englund; Michael Boeckh
Journal:  Blood       Date:  2009-12-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.